000 03259nam a22005295i 4500
001 978-3-319-67932-7
003 DE-He213
005 20210201191422.0
007 cr nn 008mamaa
008 180328s2018 gw | s |||| 0|eng d
020 _a9783319679327
_9978-3-319-67932-7
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
082 0 4 _a614.5999
_223
245 1 0 _aResistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
_h[electronic resource] /
_cedited by Yosef Yarden, Moshe Elkabets.
250 _a1st ed. 2018.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2018.
300 _aXX, 242 p. 22 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v15
500 _aAcceso multiusuario
505 0 _aResistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
520 _aThis volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
541 _fUABC ;
_cTemporal ;
_d01/01/2021-12/31/2023.
650 0 _aCancer research.
650 1 4 _aCancer Research.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B11001
700 1 _aYarden, Yosef.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aElkabets, Moshe.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783319679303
776 0 8 _iPrinted edition:
_z9783319679310
776 0 8 _iPrinted edition:
_z9783030098179
830 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v15
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-67932-7
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c243266
_d243265